IRIS
PARISI, Alessandro
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.106
NA - Nord America 1.017
EU - Europa 684
SA - Sud America 359
AF - Africa 53
OC - Oceania 3
Totale 3.222
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 971
SG - Singapore 364
BR - Brasile 290
CN - Cina 269
HK - Hong Kong 238
IT - Italia 198
RU - Federazione Russa 185
VN - Vietnam 141
DE - Germania 80
FR - Francia 42
IE - Irlanda 34
GB - Regno Unito 31
AR - Argentina 30
IN - India 23
MX - Messico 23
CI - Costa d'Avorio 22
FI - Finlandia 22
NL - Olanda 22
AT - Austria 19
CA - Canada 19
ID - Indonesia 14
SE - Svezia 14
BD - Bangladesh 11
EC - Ecuador 11
JP - Giappone 11
ZA - Sudafrica 11
PL - Polonia 9
EG - Egitto 7
ES - Italia 7
PY - Paraguay 7
CO - Colombia 6
LT - Lituania 6
CL - Cile 5
KR - Corea 5
MA - Marocco 5
TR - Turchia 5
IQ - Iraq 4
KZ - Kazakistan 4
PE - Perù 4
UA - Ucraina 4
AE - Emirati Arabi Uniti 3
AU - Australia 3
BG - Bulgaria 3
KE - Kenya 3
PK - Pakistan 3
VE - Venezuela 3
BO - Bolivia 2
BY - Bielorussia 2
IL - Israele 2
SA - Arabia Saudita 2
TN - Tunisia 2
TW - Taiwan 2
AL - Albania 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
CH - Svizzera 1
CY - Cipro 1
CZ - Repubblica Ceca 1
DZ - Algeria 1
GR - Grecia 1
GT - Guatemala 1
HN - Honduras 1
JM - Giamaica 1
MU - Mauritius 1
NG - Nigeria 1
NP - Nepal 1
PA - Panama 1
SK - Slovacchia (Repubblica Slovacca) 1
UY - Uruguay 1
UZ - Uzbekistan 1
Totale 3.222
Salva come PNG Salva come JPEG
Città #
Hong Kong 236
Ashburn 224
Singapore 216
Dallas 164
Boardman 89
Beijing 66
Ho Chi Minh City 63
Hefei 61
Los Angeles 50
Munich 41
Moscow 39
Dublin 32
The Dalles 32
São Paulo 27
Abidjan 22
Hanoi 22
Shenzhen 22
Buffalo 19
Nuremberg 19
Chandler 17
Chicago 17
Ancona 16
Fairfield 15
Rome 15
New York 14
Mexico City 12
Zhengzhou 12
Brasília 11
Camerino 11
Helsinki 11
Montreal 11
Seattle 11
Tokyo 11
Des Moines 10
Milan 10
Turku 10
Vienna 10
Houston 9
Santa Clara 9
Chennai 8
Jacksonville 8
London 8
Shanghai 8
Urbisaglia 8
Warsaw 8
Elk Grove Village 7
Rio de Janeiro 7
Washington 7
Ann Arbor 6
Bari 6
Bologna 6
Denver 6
Guangzhou 6
Orem 6
Salt Lake City 6
Secaucus 6
Amsterdam 5
Atlanta 5
Boston 5
Campinas 5
Can Tho 5
Florence 5
Goiânia 5
Lawrence 5
Miami 5
Naples 5
Phoenix 5
Princeton 5
Saint Louis 5
San Francisco 5
Seoul 5
Stockholm 5
Thái Bình 5
Asunción 4
Belo Horizonte 4
Biên Hòa 4
Columbus 4
Da Nang 4
Dhaka 4
Haiphong 4
Johannesburg 4
Kampong Loyang 4
Lima 4
Matelica 4
Porto Alegre 4
Quito 4
St Petersburg 4
Brooklyn 3
Buenos Aires 3
Cairo 3
Campos dos Goytacazes 3
Cape Town 3
Concord 3
Cotia 3
Easley 3
Guarulhos 3
Ipatinga 3
Joinville 3
João Pessoa 3
Loreto 3
Totale 1.983
Salva come PNG Salva come JPEG
Nome #
Adjuvant treatment with Capecitabine in patients who received orthotopic liver transplantation with incidental diagnosis of intrahepatic cholangiocarcinoma. Implications on DPYD polymorphisms assessment: report of two cases and review of the literature 152
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable 123
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study 97
SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry 70
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM) 68
Primary versus secondary antiemetic prophylaxis with NK1 receptor antagonists in patients affected by gastrointestinal malignancies and treated with a doublet or triplet combination regimen including oxaliplatin and/or irinotecan plus fluoropyrimidines: A propensity score matched analysis 67
The PERSONS score: A new tool for cancer patients' symptom assessment in simultaneous care and home care settings 66
COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry 65
Concurrent RAS and RAS/BRAF V600E Variants in Colorectal Cancer: More Frequent Than Expected? A Case Report 63
Current Evidence and Future Perspectives about the Role of PARP Inhibitors in the Treatment of Thoracic Cancers 63
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma 59
Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer 59
Pemigatinib in pazienti affetti da colangiocarcinoma localmente avanzato o metastatico con fusione o riarrangiamento di FGFR2 pretrattati: analisi congiunta degli studi di coorte multicentrici, osservazionali, "real-world" francese PEMI-BIL e italiano PEMI-REAL 57
Conversion Strategy in Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer Patients with Unresectable Liver-Limited Disease: A Multicenter Cohort Study 57
Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status 56
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer 55
Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study 54
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study 53
Evaluation of prognostic factors for survival in transverse colon cancer 53
Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study 52
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours 52
Communication in oncology between healthcare providers, patients, the scientific community, and the media: recommendations from the Italian Association of Medical Oncology (AIOM) 50
Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies 49
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population 47
Changes in clinical presentation, management, and survival outcomes in patients affected by colorectal cancer following COVID-19 pandemic 46
COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry 45
Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study 45
The dynamics of circulating tumour DNA (ctDNA) during treatment reflects tumour response in advanced melanoma patients 45
Immune Checkpoint Inhibitors and Myasthenic Syndromes: A Case Report of a Metastatic Renal Cell Carcinoma Patient Treated With Nivolumab 44
Comparison Between First Line Target Therapy and Immunotherapy in Different Prognostic Categories of BRAF Mutant Metastatic Melanoma Patients: An Italian Melanoma Intergroup Study 44
Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry 44
First-line carboplatin/nab-paclitaxel in advanced ovarian cancer patients, after hypersensitivity reaction to solvent-based taxanes: a single-institution experience 43
A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement? 43
The emerging role of immunotherapy in the treatment of anal cancer 43
Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction 42
Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE study 41
Immunotherapy in Triple-Negative Breast Cancer 41
Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: A retrospective multicenter study 40
The Interplay between Anti-Angiogenics and Immunotherapy in Colorectal Cancer 39
What is known about theragnostic strategies in colorectal cancer 39
How to best exploit immunotherapeutics in advanced gastric cancer: Between biomarkers and novel cell-based approaches 38
Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer 38
Family History of Cancer as Potential Prognostic Factor in Stage III Colorectal Cancer: a Retrospective Monoinstitutional Study 38
Comparison of different second line treatments for metastatic pancreatic cancer: a systematic review and network meta-analysis 37
The treatment paradigm of right-sided metastatic colon cancer: harboring BRAF mutation makes the difference 37
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment 37
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 37
Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study 36
Multimodality treatment in metastatic gastric cancer: From past to next future 36
Time-Dependent COVID-19 Mortality in Patients with Cancer: An Updated Analysis of the OnCovid Registry 36
Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab 35
Bone recurrence in early breast cancer patients: The paradox of aromatase inhibitors induced bone resorption 34
A case of segmental hepatic necrosis complicating oxaliplatin and capecitabine chemotherapy: A case report and review of the literature 33
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational study 32
Post-induction Strategies in Metastatic Colorectal Cancer Patients Treated With First-Line Anti-EGFR-Based Treatment: A Systematic Review and Meta-Analysis 32
Haloperidol for the treatment of opioid addiction in advanced cancer patients: a case series 31
Aflibercept-Based and Bevacizumab-Based Second Line Regimens in Patients with Metastatic Colorectal Cancer: Propensity Score Weighted-Analysis from a Multicenter Cohort 30
Looking for a place for dose-dense TMZ regimens in GBM patients: An experience with MGMT exploratory evaluation 30
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience 29
Timed-flat infusion of 5-fluorouracil with docetaxel and oxaliplatin as first-line treatment of gastroesophageal adenocarcinoma: A single institution experience with the FD/FOx regimen 29
Topical menthol for treatment of chemotherapy-induced peripheral neuropathy 28
The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A ‘hypothesis-generator’ study from clinical practice 26
Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: Preliminary report of the FAMI-L1 study 25
The PERSONS score for symptoms assessment in simultaneous care setting: A pilot study 24
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study 24
Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: An update from clinical practice 24
Is it a new era for intrahepatic cholangiocarcinoma? 23
Where are we with treatment options after first line in small cell lung cancer?-Report of two opposite cases treated with CAPTEM regimen and possible perspectives 23
Multicentric retrospective analysis of platinum-pemetrexed regimens as first-line therapy in non-squamous non-small cell lung cancer patients: A “snapshot” from clinical practice 23
Expression of pro-angiogenic factors as potential biomarkers in experimental models of colon cancer 22
Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature 22
Single-institution study of correlations between skeletal muscle mass, its density, and clinical outcomes in non-small cell lung cancer patients treated with first-line chemotherapy 20
Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study 20
Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: A “hypothesis-generator” preliminary report 19
MITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)–Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors—A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control Study 19
Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain–Barré Syndrome 16
null 16
Into the storms: Organising oncological home care services during natural disasters and global pandemics 15
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC‐D Index 15
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population 12
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population 12
Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis 12
SHORT-COURSE RADIOTHERAPY FOR OLDER PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER AND UNFIT FOR CHEMOTHERAPY: THE SOFT STUDY 10
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab 8
null 7
null 7
null 6
null 2
Totale 3.436
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.116
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.116
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202117 0 0 0 0 0 0 0 5 2 4 2 4
2021/202231 0 2 0 0 0 2 1 1 13 1 6 5
2022/202371 5 3 4 10 0 11 0 2 18 7 10 1
2023/2024254 16 3 13 19 18 27 2 13 1 71 25 46
2024/20251.356 151 76 42 12 39 50 200 67 274 96 115 234
2025/20261.681 213 343 198 487 374 66 0 0 0 0 0 0
Totale 3.436